XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Total revenue $ 40,134 $ 15,735 $ 120,614 $ 106,367
Operating costs and expenses:        
Cost of goods sold $ 4,243 $ 4,308 $ 13,441 $ 15,355
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 61,194 $ 75,182 $ 231,158 $ 235,163
Selling, general and administrative 25,573 29,902 91,029 90,722
Restructuring charge 12,606 0 12,606 0
Total operating costs and expenses 103,616 109,392 348,234 341,240
Loss from operations (63,482) (93,657) (227,620) (234,873)
Interest and other, net        
Interest expense (5,022) (84) (10,464) (321)
Interest income and other income (expenses), net 4,296 1,798 7,984 6,672
Total interest and other, net (726) 1,714 (2,480) 6,351
Loss before income taxes (64,208) (91,943) (230,100) (228,522)
Provision for (benefit from) income taxes 84 114 (77) 250
Investment income in unconsolidated variable interest entity 677 407 2,023 1,293
Net loss $ (63,615) $ (91,650) $ (228,000) $ (227,479)
Net loss per share - basic $ (0.65) $ (0.98) $ (2.35) $ (2.43)
Net loss per share - diluted $ (0.65) $ (0.98) $ (2.35) $ (2.43)
Weighted average number of common shares used to calculate net loss per share:        
Basic 98,245 93,767 96,901 93,431
Diluted 98,245 93,767 96,901 93,431
License Revenue [Member]        
Revenue:        
Total revenue $ 2,649 $ 0 $ 9,649 $ 22,590
Development and Other Revenue [Member]        
Revenue:        
Total revenue 6,775 2,453 15,825 19,672
Product Revenue, Net [Member]        
Revenue:        
Total revenue 29,390 17,359 77,439 59,495
Drug Product Revenue, Net [Member]        
Revenue:        
Total revenue $ 1,320 $ (4,077) $ 17,701 $ 4,610